Comparative In Vitro Activity of Tigecycline Against Bacteria Recovered from Clinical Specimens in Latin America

REFERENCES

• Tenover FC. Mechanisms of antimicrobial resistance in bac-teria. Am J Med 2006; 119 (Suppl 1):53–10.
   Google Scholar
• John J, Fishman N. Programatic role of the infectious dis-eases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24: 471–85.
   PubMed Web of Science ®Google Scholar
• Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to an-tibiotics in developing countries. Emerg Infect Dis 1999; 5: 18–27.
   PubMed Web of Science ®Google Scholar
• Bantar C, Famiglietti A, Goldberg M, The Antimicrobial Committee and The National Surveillance Program (SIR) Partic-ipants Group. Three-year surveillance study of nosocomial bac-terial resistance in Argentina. Int J Infect Dis 2000 ; 4 :85–90.
   Google Scholar
• Alvarez C, Cortes J, Arango A, Correa C, Leal A; Grupo para el Control de la Resistencia Bacteriana en Bogota. Anti-mi-crobial resistance in intensive care units in Bogota, Colombia, 2001-2003. Rev Salud Publica (Bogota) 2006; 8 (Suppl 1):86-101.
   Google Scholar
• Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57: 7–13.
   PubMed Web of Science ®Google Scholar
• Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-struc-ture infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41 (suppl):5315-5332.
   Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43: 738–744.
   PubMed Web of Science ®Google Scholar
• Babinchak T, Ellis-Grosse E, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline for the treatment of com-plicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41: 354–67.
   PubMed Web of Science ®Google Scholar
• Grosse-Ellis E, Babinchak T, Dartois N., Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections. Clin Infec Dis 2005; 41: 341–53.
   Web of Science ®Google Scholar
• Murray P, Baron E, Pfaller M, Tenover F, Yolken R (eds). Manual of Clinical Microbiology, 6th edn, Washington D.C., American Society for Microbiology, 1995.
   Google Scholar
• Clinical and Laboratory Standards Institute. 2006. Per-formance standards for antimicrobial disk susceptibility tests; approved standard M2-A9, 9th ed. CLSI, Wayne, PA, 2006.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; M100-516, 16th informational supplement CLSI., CLSI, Wayne, PA, 2006.
   Google Scholar
• Jones RN, Ferraro MJ, Beller LB, Schreckenberger PC, Swenson JM, Sander HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Mi-crobiol 2007; 45: 227–30.
   PubMed Web of Science ®Google Scholar
• Okeke IN, Lamikanra A, Edelman R. Socioeconomic and behavioral factors leading to acquired bacterial resistance to an-tibiotics in developing countries. Emerg Infect Dis 1999; 5: 18–27.
   PubMed Web of Science ®Google Scholar
• Levy SB. (ed.). The antibiotic paradox: how the miracle drugs are destroying the miracle, 1st. edn. New York, Plenum Press. 1992.
   Google Scholar
• Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect 2008; 14 Suppl 1: 154–8.
   PubMed Web of Science ®Google Scholar
• Radice M, Power P, Gutkind G, et al. First class a car-bapenemase isolated from Enterobacteriaceae in Argentina. An-timicrob Agents Chemother 2004; 48: 1068–9.
   PubMed Web of Science ®Google Scholar
• Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. An-timicrob Agents Chemother 2006; 50: 2880–2.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Sader HS, Deshpande LM, Fritsche TR, Jones RN. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase-and metallo-lbetal-lactamase-producing Enterobacteriaceae: Report from the SENTRY Antimicrobial Surveillance Program. An-timicrob Agents Chemother 2008; 52: 570–3.
   PubMed Web of Science ®Google Scholar
• Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J An-timicrob Agents 2007; 30: 525–9.
   PubMed Web of Science ®Google Scholar
• Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, Canton R. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 60: 319–22.
   PubMed Web of Science ®Google Scholar
• Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edel-stein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46: 567–70.
   PubMed Web of Science ®Google Scholar
• Gales AC, Sader H HS, Jones RN. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: frequency of occurrence and an-timicrobial susceptibility profile: results from the SENTRY An-timicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44: 301–11.
   PubMed Web of Science ®Google Scholar
• Bantar C, Famiglietti A, Radice M, Quinteros M, Antimi-crobial Committee, Sir Participants Group. A 7-year national sur-vey on bacterial resistance in bronchoalveolar lavage from patients hospitalized in Argentina. Diagn Microbiol Infect Dis 2008; 60: 65–9.
   PubMed Web of Science ®Google Scholar
• Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY An-timicrobial Surveillance Program. Int J Infect Dis 2004; 8: 284–91.
   Google Scholar
• Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, Woodford N, Livermore D, Quinn JP. Dissemination of Acinetobacter baumannii clones with OXA-23 Carbapenemase in Colombian hospitals. Antimicrob Agents Chemother 2007; 51: 2001–4.
   PubMed Web of Science ®Google Scholar
• Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter bau-mannii. Pharmacotherapy 2007; 27: 980–87.
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005; 9: 348–56.
   PubMedGoogle Scholar
• Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, Nicolau DP. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49: 1629–32.
   PubMed Web of Science ®Google Scholar
• Thamlikitkul V and Tiengrim S. Effect of different Mueller-Hinton agars on tigecycline disc diffusion susceptibility for Acine-tobacter spp. J Antimicrob Chemother 2008; 64: 847–8.
   Google Scholar